Zobrazeno 1 - 10
of 36
pro vyhledávání: '"RYOTARO OHKUMA"'
Autor:
Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi, Akiko Sasaki, Yuta Baba, Yoichiro Narikawa, Hitoshi Toyoda, Junya Isobe, Eiji Funayama, Kohei Tajima, Aya Sasaki, Yuki Maruyama, Yoshitaka Yamazaki, Midori Shida, Kazuyuki Hamada, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Shinichi Kobayashi, Toshikazu Shimane, Takuya Tsunoda, Hitome Kobayashi, Yuji Kiuchi, Kiyoshi Yoshimura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In particular, intestinal bacteria and their metabolit
Externí odkaz:
https://doaj.org/article/7f87f822bfdf411aabf1cc2f6ca5007b
Autor:
Yuya Hirasawa, Yutaro Kubota, Emiko Mura, Risako Suzuki, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, Atsushi Horiike, Satoshi Wada, Takeshi Yamashita, Tomotake Ariyoshi, Satoru Goto, Koji Otsuka, Masahiko Murakami, Yuji Kiuchi, Kiyoshi Yoshimura, Takuya Tsunoda
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionImmune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for esophageal cancer (EC). Although ICIs enable long-term survival in some patients, the efficacy of ICIs varies widely among patients. Therefore, predictiv
Externí odkaz:
https://doaj.org/article/ec9c13c60c4d45eb834f44c57b5372fe
Autor:
Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/1afbfe292d48439c963acc6084437cfe
Autor:
Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-
Externí odkaz:
https://doaj.org/article/79df360ee61b4247bc78ebaffe4da883
Autor:
Ryotaro Ohkuma, Sakiko Miura, Satoshi Muto, Yoshitaka Toyomasu, Yuki Fujimoto, Katsuaki Ieguchi, Nobuyuki Onishi, Takashi Shimizu, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Atsushi Horiike, Kazuyuki Hamada, Hirotsugu Ariizumi, Masahiro Shimokawa, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Toshiaki Tsurui, Emiko Mura, Sachiko Takenoshita, Kazuki Numajiri, Naoyuki Okabe, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Toshiki Yajima, Hideyuki Ishida, Hiroyuki Suzuki, Toshiko Yamochi, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionProgrammed cell death ligand 1 (PD-L1) expression in tumor tissues is measured as a predictor of the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in many cancer types. PD-L1 expression is evaluated by immunohistochemical st
Externí odkaz:
https://doaj.org/article/ae7a3794a1b04272bd831501907f335c
Autor:
Risako Suzuki, Kazuyuki Hamada, Ryotaro Ohkuma, Mayumi Homma, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Yutaro Kubota, Atsushi Horiike, Kiyoshi Yoshimura, Satoshi Wada, Toshiko Yamochi, Takuya Tsunoda
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundCancer of unknown primary (CUP) is a malignant tumor without a known primary lesion with a frequency of 3−5%. It can be divided into favorable and unfavorable prognosis subsets. While recommended treatments are available for the former gr
Externí odkaz:
https://doaj.org/article/e2477a64a1da4c75b2af29bfc6cb2d4a
Autor:
Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda, Kiyoshi Yoshimura
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, su
Externí odkaz:
https://doaj.org/article/3baf4a74bec646c1a17af2830c7a875b
Autor:
Ryotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Rie Onoue, Kazuyuki Hamada, Yutaro Kubota, Atsushi Horiike, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Junji Tsurutani, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Biomedicines, Vol 9, Iss 12, p 1929 (2021)
Immune checkpoint inhibitors (ICIs) confer remarkable therapeutic benefits to patients with various cancers. However, many patients are non-responders or develop resistance following an initial response to ICIs. There are no reliable biomarkers to pr
Externí odkaz:
https://doaj.org/article/233a7fcb10684854adad9aa44c898b58
Autor:
Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa, Daisuke Komura, Hidenobu Ishizaki, Koji Tamada, Yutaro Kubota, Kazuyuki Hamada, Hiroo Ishida, Yuya Hirasawa, Hirotsugu Ariizumi, Etsuko Satoh, Midori Shida, Makoto Watanabe, Rie Onoue, Kiyohiro Ando, Junji Tsurutani, Kiyoshi Yoshimura, Takehiko Yokobori, Tetsuro Sasada, Takeshi Aoki, Masahiko Murakami, Tomoko Norose, Nobuyuki Ohike, Masafumi Takimoto, Masahiko Izumizaki, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0226707 (2020)
Pancreatic cancer has an extremely poor prognosis, and identification of novel predictors of therapeutic efficacy and prognosis is urgently needed. Chemoresistance-related molecules are correlated with poor prognosis and may be effective targets for
Externí odkaz:
https://doaj.org/article/2516b1d1f4a1457cbd0daf1c90b6b292
Autor:
Tomoyuki Ishiguro, Daisuke Takayanagi, Toshiaki Tsurui, Risako Suzuki, Nana Iriguchi, Yuya Hirasawa, Ryotaro Ohkuma, Hirotsugu Ariizumi, Yutaro Kubota, Kazuyuki Hamada, Atsushi Horiike, Satoshi Wada, Kiyoshi Yoshimura, Kazuyoshi Takeda, Takuya Tsunoda
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::620df439a8eee97e9741416a4403f6b6
https://doi.org/10.1136/jitc-2022-sitc2022.0046
https://doi.org/10.1136/jitc-2022-sitc2022.0046